GlassScriptPhysician profile
Emil W Chynn
NPI 1346272911
$4,196.59
in general payments reported to CMS, 2019-2025
17 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $207 · 2021: $946 · 2022: $639 · 2023: $669 · 2024: $738 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $883.42 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $545.55 | 2024-2025 | Ilevro |
| Eyevance Pharmaceuticals LLC | $444.79 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $393.16 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Kala Pharmaceuticals, INC. | $337.97 | 2019-2022 | |
| Alcon Vision LLC | $279.94 | 2023-2024 | Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $262.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $260.54 | 2020-2023 | |
| Dompe US, INC. | $206.08 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $180.03 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $129.57 | 2020-2021 | |
| Horizon Therapeutics Plc | $122.43 | 2022 | |
| Allergan, INC. | $43.52 | 2021 | |
| Sight Sciences, INC. | $38.98 | 2021 | |
| Shire North American Group INC | $23.44 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $22.94 | 2024 | Iluvien, Yutiq |
| Biotissue Holdings INC. | $21.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Chynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.